With the evolution of covid variants, i believe this is one of the possible solution to serious covid reactions. It is competitors of course are vaccine makers.
Are we going to keep relying on vaccine makers. Or can we rely on something like what ENLV has?
Based on my research, ENLV is in the midst of trials and so far seems to be the only Israeli company,...
Just hold this doesn't break below this trendline. Otherwise, it will likely head to 5.
the RSI and MACD is already showing it is oversold.The last time it was 6.50 was awhile back.
$ENLV Target 17.10 for 31.34%
Or next add level is at 8.94
Anywhere around here is a good place to add...
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed and as possible.
I am not...
$ENLV Target 18.02 for 29.27%
Or next add level is at 9.86
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed and as possible.
I am not your financial advisor. Watch my setups first...
$ENLV Target 19.39 for 26.65%
Or next add level is at anywhere around here but I can’t add yet.
This one is actually really starting to look bullish... running out of steam on the down side... I am going to double my position here tomorrow, I think. There are a few other moves I'm thinking about but this one feels solid right now.
—
On the far right of the...
ADDED to $ENLV Target 20.08 for 25.50%
Or next add level is at 11.92
I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk...
Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors.
In addition to the Sepsis for which it was developed, the drug Allocetra has other applications such as severe patients with Covid 19 '
autoimmune diseases.
Indication Global Market Size Pre Clinical Phase ...
ENLV spikes on Report for Positive Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients . Anice momentum up for a intraday trading.
#ENLV is in the news last week with regards to Covid-19 treatment.
I would be looking at the 18.46 area for a retest, and possible entry if we find support.
100% measured move would take the breakout to 23.81 and ultimately that would be my first target.
Id consider this trade still healthy above 15.49 and ultimately any lower than 14.54 i would stop out of a...
-EXO-CD24 was tested on Covid patients at Ichilov Medical Center in Tel Aviv-
-Some 29 out of 30 patients suffering moderate to severe conditions recovered
-Drug was developed to treat cancer by regulating immune system responses
The drug Allocetra saves the lives of patients in a severe condition from the virus in Israel.
The end of the Phase 2 trial is about to be published soon.
preventing or treating complications associated with sepsis, COVID-19, bone-marrow transplants and solid tumors.
At the end of 2021, the drug report on patients will be published.
Last chance before takeoff.
...
Sepsis is currently the number three cause of death in the Western world, after heart-lung failure and cancer. This is a market of more than $ 30 billion.
The Enlv product was originally intended for the treatment of sepsis (sepsis) and is in 2nd place in drug trials. The drug developed by Enlv is supposed to over-activate the immune system in patients with...
I found this pattern at tickeron website with the following data:
STATUS = Confirmed
CURRENT CONFIDENCE = 80%
TARGET (EXIT) PRICE = 11.30 USD
BREAKOUT (ENTRY) PRICE = 12.60 USD
DISTANCE TO TARGET PRICE = 6.92%
EMERGED ON = Oct 23, 11:00 AM (EDT)
CONFIRMED ON = Oct 23, closing price
WITH CONFIDENCE LEVEL = 87%
The Inverted Cup-and-Handle (sometimes called...
